Closed to Enrollment
A phase 2, double-masked, randomized, parallel-group study to investigate the safety, tolerability and efficacy of GSK933776 in adult patients with geographic atrophy (GA) due to age-related macular degeneration (AMD).
- Adult patients >55 years of age inclusive at the time of signing the informed consent.
- Evidence of AMD confirmed by the presence of at least 1 druse >125 µm diameter in either eye.
- Well-demarcated GA due to AMD of total area 1.9-17 mm2 measured on color fundus photographs and fundus autofluorescence in the study eye.
- Best-corrected ETDRS visual acuity score (approximately 20/200 Snellen VA equivalent) in the study eye. If both eyes are eligible for the study, the eye with the better BCVA score is selected as the study eye.